AB0710 IXEKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED OVERALL HEALTH AS MEASURED BY SF-36 IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS NAIVE TO BIOLOGICAL THERAPY: 52 WEEK RESULTS OF A PHASE 3 TRIAL

James Cheng-Chung WeiFilip van den BoschJessica a. WalshUta KiltzTheresa HunterYan DongAnn LeungDavid SandovalLuis LeonVibeke Strand2026-01-292026-01-292019-0610.1136/annrheumdis-2019-eular.1612https://scholars.csmu.edu.tw/handle/123456789/3837AB0710 IXEKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED OVERALL HEALTH AS MEASURED BY SF-36 IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS NAIVE TO BIOLOGICAL THERAPY: 52 WEEK RESULTS OF A PHASE 3 TRIALjournal-article